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The Bcl-2 family consists of about 20 homologues of important pro- and anti-apoptotic regulators of programmed cell death. The
established mode of function of the individual members is to either preserve or disturb mitochondrial integrity, thereby inducing or preventing
release of apoptogenic factors like Cytochrome c (Cyt c) from mitochondria. Recent findings also indicate further Bcl-2-controlled
mitochondria-independent apoptosis pathways. Bcl-2 represents the founding member of the new and growing class of cell death inhibiting
oncoproteins. In this review, we try to briefly summarize current models of Bcl-2 family function and to outline the work demonstrating the
influence of deregulated Bcl-2 family member expression on tumorigenesis and cancer therapy. Since several Bcl-2 homologues, in addition
to influencing apoptotic behaviour, also impinge on cell cycle progression, we discuss possible implications of this additional role for the
expression of Bcl-2 family members in tumor cells.
D 2003 Elsevier B.V. All rights reserved.Keywords: Bcl-2 family; Tumorigenesis; Cell cycle; Chemoresistance; Radiation; Clinical therapy1. Introduction
Proper homeostasis of tissues and organs is achieved by a
tight control of cell turnover. Lineage-specific stem cells
start to proliferate and differentiate if substitution of aging
and lost cells is needed. On the other hand, unwanted,
dangerous or surplus cells are removed by apoptosis, a form
of programmed cell death which results in degradation of
the dead cells without inflammation [1]. When the homeo-
static balance is disturbed in such a way that cell growth is
no longer restricted, clonal outgrowth of mutated cell
populations may occur, resulting in the development of a
tumor. Available data and animal models support the hy-
pothesis that tumorigenesis requires impairment of apopto-
sis [2].
A tumor cell is exposed to a variety of different apopto-
sis-inducing stimuli. Early in transformation, activated
oncogenes which drive the cell into uncontrolled prolifera-
tion simultaneously trigger the cell death programme. This
may reflect a built-in safety mechanism which removes cells
with mutations in oncogenes like c-myc, c-fos or c-jun [3].0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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E-mail address: zoernig@em.uni-frankfurt.de (M. Zo¨rnig).Later during tumorigenesis, the supply of nutrients and
oxygen becomes limited and the tumor cells undergo
hypoxia-induced apoptosis [4]. If cells start to detach from
the primary tumor mass, they lose survival signals provided
by cell–cell contacts and local cytokines [5]. To survive
such hostile conditions, tumor cells must acquire apoptosis-
inhibiting mutations. Nevertheless, the conversion of normal
cells into tumor cells requires more than the suppression of
apoptosis. Constant (short-cut) proliferative signalling and
the ability to overcome senescence are required simulta-
neously for cell transformation [2]. However, the impor-
tance of apoptosis inhibition during the process of
tumorigenesis has been recognized, and the ongoing dis-
covery of numerous apoptosis-regulating proteins provides
new potential targets for a molecular cancer therapy. Among
such targets are the members of the Bcl-2 family, and this
review aims to summarize the work which links deregula-
tion of Bcl-2 homologues to tumor development.2. The Bcl-2 family: general considerations
The core apoptotic machinery in the model system C.
elegans consists of three interacting proteins: CED3, CED4
and CED9 (for review see Ref. [6]). The CED3/CED4 dimer
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Activation of CED3 by CED4 is inhibited as long as CED9
is associated with this moiety. When the transcriptionally
up-regulated EGL1 protein binds to the apoptosis-inhibitor
CED9, thereby removing this molecule from the CED3/
CED4 complex, the cell death programme is executed.
Mammalian homologues for all of these C. elegans mole-
cules have been identified. CED3 resembles the caspase
family members and the recently discovered Apaf-1 was
found to be a mammalian CED4 homologue. Relatives of
CED9 and EGL1 belong to the Bcl-2 family which consists
of at least 20 members in mammals.
The Bcl-2 homologues fall into three classes, all of which
share at least one conserved Bcl-2 homology (BH) domain
(Fig. 1).
2.1. Class 1: the Bcl-2-like survival factors
The Bcl-2-like survival factors are described as ‘‘mem-
brane-bound scavengers of pro-apoptotic proteins’’ [7].
They contain three to four BH domains which are required
for their anti-apoptotic functions, and this group includes
Bcl-2, Bcl-xL, Bcl-w, A1/Bfl-1, Boo/Diva/Bcl-B and Mcl-1.
The BH1–BH4 domains mediate interactions with other
protein partners and the molecules localize to the cytoplas-
mic faces of intracellular membranes, such as the outer
mitochondrial membrane, the endoplasmic reticulum and
the nuclear envelope. The BH1–BH3 domains form a
hydrophobic groove, and the N-terminal BH4 domain
stabilizes this structure from the backside by burying further
hydrophobic residues which would otherwise be exposed
(e.g. Ref. [8]). The hydrophobic groove can bind the BH3
a-helix of an interacting (pro-apoptotic) Bcl-2 family mem-
ber [9]. In Bcl-w, the groove can be occupied by its own
carboxy-terminal tail, in a manner similar to Bax [10]. In
this situation, an interacting BH3 ligand might need to
displace the tail. Under physiological conditions, not all
BH3-containing proteins can interact with the hydrophobic
groove of Bcl-2 survival factors. While pro-apoptotic BH3-
only and Bax-like proteins (see below) expose their BH3
domain after a posttranslational modification and/or a con-
formational change, death-inhibiting Bcl-2 homologues
maintain this domain as an integral part of their hydrophobic
pocket [11]. Their BH3 domains are not available for
binding to other hydrophobic pockets of Bcl-2 family
members, which explains why, for example, Bcl-2 and
Bcl-xL cannot oligomerize.Fig. 1. Bcl-2 protein domain organisation (adopted from Ref. [28]). Abbreviation
known alpha-helical regions.As a response to certain apoptotic stimuli, Bcl-2-like
survival factors are converted into pro-apoptotic proteins
after proteolytic removal of the N-terminal BH4 domain
[12].
2.2. Class 2: Bax-like death factors mediate apoptosis after
conformational change and pore formation
Bax-like death factors contain BH1–BH3 domains. This
subfamily of Bcl-2 homologues acts exclusively in a pro-
apoptotic fashion and consists of the mammalian family
members Bax, Bak and Bok/Mtd. While Bax and Bak are
widely expressed [13,14], Bok expression appears to be
restricted to reproductive tissues [15]. Mouse genetic data
suggest that the presence of either Bax or Bak is essential
for apoptosis in many cell types [16,17]. In Bax, the BH3
helix is less packed to the hydrophobic core than in Bcl-xL,
and this flexibility of the BH3 domain allows it to bind to
the hydrophobic grooves of Bcl-2-like survival factors
[7,10]. Swapping the BH3 domain from Bax to Bcl-2
converts the latter to a death agonist despite the presence
of the BH4 region [18]. Absence of the BH4 domain in
Bax-like proteins in contrast to Bcl-2 was initially thought
to be responsible for the pro-apoptotic characteristic of this
subclass.
The C-terminal tail of Bax is folded back into its
hydrophobic pocket mimicking the binding of pro-apoptotic
BH3 peptides to the hydrophobic pocket of anti-apoptotic
Bcl-2 family members [10]. This folding prevents Bax from
binding to membranes, and unleashing the C terminus
results in mitochondrial targeting upon apoptotic triggering
[19]. Bak and Bok, on the other hand, are exclusively
membrane-bound in healthy cells and do not require extra
translocation in apoptotic cells [20].
Once they are attached loosely to the mitochondrial
membrane, Bax-like death factors undergo an activating
conformational change which leads to their stable insertion
into the membrane [7]. These molecules then either form
channels (e.g. Ref. [21]) or interact with channel-forming
proteins to increase the permeability of the outer mitochon-
drial membrane [22,23]. Whether Bax-like death factors
need to oligomerize for their pro-apoptotic function is a
matter of debate (e.g. Refs. [7,24–26]; for a detailed
discussion see Ref. [7]). Kuwana et al. [27], for example,
conclude from their cell-free studies using ‘‘mitochondrial
outer membranes’’ that mitochondrial protein release during
apoptosis can be mediated by supramolecular openings ins: BH1-4, Bcl-2 homology domains; TM, transmembrane domain; a1–7,
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activated by BH3-only proteins like Bid, and the mitochon-
dria-specific lipid cardiolipin is important not only for the
membrane targeting of Bid, but also for the permeabilization
function of Bax. Massive Bax oligomerization does not
seem to be necessary for the protein-releasing function of
Bax, and the authors find evidence for tetramer-sized Bax
complexes. These findings are inconsistent with a mecha-
nism involving the formation of discrete protein channels by
Bax.
2.3. Class 3: the pro-apoptotic BH3-only Bcl-2 family
The BH3-only death factors share only the short BH3
domain with the other Bcl-2 family subclasses (and with
each other). The 10 or more so far identified BH3-only
proteins in mammals represent homologues of the pro-
apoptotic C. elegans protein EGL1. With the exception of
Bid and possibly Bim, they are thought to act by binding to
and neutralizing the Bcl-2-like survival factors [28]. Bid
might also inactivate anti-apoptotic Bcl-2 family members
but, in addition, it seems to transduce cell death signals by
activating Bax and Bak for their Cyt c-releasing function
[29,30]. The results for Bim are contradictory. The intact
Bim protein binds and antagonizes Bcl-2 and Bcl-xL func-
tion and seems unable to interact with Bax or Bak. How-
ever, the isolated Bim BH3 domain, when removed from the
context of the entire protein, is capable of inducing oligo-DR
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very much like the Bid BH3 domain [31]. Bim has also been
suggested to directly interact with and activate the voltage-
dependent anion channel VDAC [32] and/or to activate Bax
by damaging the mitochondrial membrane structure directly
[33].
BH3-only proteins act upstream of Bax-like death fac-
tors as they are not able to induce cell death in the absence
of Bax and Bak [17]. They are described as the ‘‘sensors
and mediators of apoptosis’’ and individual BH3-only
proteins might transduce different and specific death signals
to the multidomain Bcl-2 family members (see Ref. [34]
and references therein). Bim for example is important for
the cell death of lymphocytes upon cytokine deprivation
[35], Bmf is required for apoptosis triggered by cell
detachment (anoikis [36]) and Noxa and Puma seem to
mediate P53-induced apoptosis as a consequence of DNA
damage [37–39].
In healthy mammalian cells, BH3-only proteins are kept
inactive [28]. In response to pro-apoptotic signals, they
become transcriptionally up-regulated and/or posttransla-
tionally modified (or relocalized) to gain their full pro-
apoptotic potential. Puma and Noxa are induced by P53
[37–39]; this transcriptional induction is similar to EGL1
up-regulation in C. elegans.
Bad and Bik are two BH3-only proteins which are
regulated by phosphorylation. In cells which are protected
against apoptosis by cytokines, Bad is phosphorylated atBak†
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Table 1
Chromosomal positions of bcl-2 gene family members and tumor types
frequently affected by copy number changes of the corresponding
chromosomal regions
Gene Chromosome
locus
Tumors with frequent
numerical changes
Frequency
bcl-2 18q21 Acute lymphoblastic
leukemia (ALL)
enh 8/16 (50%)
Precursor B-lymphoblastic
leukemia/lymphoma
enh 2/5 (40%)
Diffuse large B-cell
lymphoma (centroblastic)
enh 14/46 (30%)
bcl-xL 20q11 Liposarcoma (pleomorphic) enh 10/13 (77%)
Squamous cell carcinoma
(oral cavity)
enh 10/14 (71%)
Meningioma enh 23/45 (51%)
Breast carcinoma (ductal) enh 11/23 (48%)
Glioblastoma enh 10/39 (26%)
Hodgkin lymphoma
(mixed cellularity)
enh 5/21 (24%)
bid 22q11.2 Meningioma dim 39/90 (43%)
Ependymoma dim 23/55 (42%)
Gastrointestinal stromal tumors dim 38/123 (31%)
bak 6p21 Meningioma dim 9/45 (20%)
bad 11q12 Lymphocyte predominance
Hodgkin lymphoma
dim 5/20 (25%)
Gastrointestinal stromal tumors dim 7/35 (20%)
Statistics were obtained from a database containing CGH results of more
than 1000 different tumors [245]. Abbreviations: enh, copy number gains;
dim, copy number losses.
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different kinases Akt/PKB and Raf; see Ref. [7] and
references therein). Phosphorylation of Bad leads to its
binding to 14-3-3 scaffold proteins and to its sequestration
in the cytoplasm [40]. Upon cytokine or extracellular matrix
withdrawal, Bad is de-phosphorylated and released from 14-
3-3 [41]. The molecule is now able to interact with Bcl-2-
like survival proteins and to neutralize their anti-apoptotic
interaction with Bax-like death factors.
The Bid molecule is cleaved by Caspase-8 in response to
Death Receptor activation (or by Granzyme B [42,43]).
Proteolysis results in exposure of the Bid BH3 domain
which is normally buried in the full-length protein [44,45].
The cleaved (p7/p15) complex is myristoylated on p15 and
translocated to mitochondria [46]. Bid seems to form
homotrimers in the mitochondrial membrane which then
may induce mitochondrial Bax and Bak to oligomerize [30].
Last but not least, the BH3-only proteins Bim and Bmf
are kept inert by sequestration to the cytoskeleton. Bim
binds to the dynein light chain LC8 (DLC1), a component
of the dynein motor complex on microtubules [47]. Bmf
interacts with the dynein light chain DLC2 of the actin
cytoskeleton-based myosin V motor complex [36]. Upon
cytokine withdrawal (Bim) or by the lack of extracellular
matrix (Bmf), both molecules are released from their bind-
ing partners, enabling them to interact with and neutralize
Bcl-2-like survival factors.
In all cases, the net balance between the pro-survival
(Bcl-2-like) and the pro-apoptotic BH3-only proteins seems
to determine the cell’s fate and the decision whether to live
or to die.
The precise biochemical function of the Bcl-2 family is
far from being understood. Nevertheless, in recent years
their impact on the mitochondrial membrane has become
the central focus of scientific interest. Two (partly
interconnected) apoptosis pathways have been delineated
(see Ref. [48] and references therein). The (extrinsic) Death
Receptor pathway is triggered by signals from other cells
and leads to direct activation of the caspase cascade at
intracellular receptor signalling complexes. The (intrinsic)
mitochondrial pathway kicks off following the induced
release of apoptogenic factors from the mitochondria.
Among such factors is Cyt c, which, together with dATP
or ATP, binds to the adaptor protein Apaf-1. This molecule
then oligomerizes and forms the ‘‘apoptosome’’ complex.
Caspase-9 is recruited to this complex and via ‘‘induced
proximity’’ becomes proteolytically activated, thereby ini-
tiating (and amplifying) effector caspase activation.
Bcl-2 family members regulate the release of Cyt c (and
other factors) from mitochondria. In general, the pro-apo-
ptotic Bcl-2 homologues Bax and Bak are inserted in the
outer mitochondrial membrane and they actively induce Cyt
c release upon their oligomerization [7], possibly by form-
ing a new channel [21], by enlarging the existing perme-
ability transition pore [22,23], or by forming supramolecular
openings in the outer mitochondrial membrane which aredifferent from discrete protein channels [27]. Such scenarios
are based on the finding that Bcl-2 family members struc-
turally resemble diphtheria toxin, a membrane-located pore-
forming molecule [49]. Anti-apoptotic family members like
Bcl-2 and Bcl-xL hold Bax and Bak in check, possibly by
forming heterodimers with these molecules, thereby pre-
serving mitochondrial integrity [7]. Direct physiological
interaction between pro- and anti-apoptotic Bcl-2 family
members in the mitochondrial membrane has not been
demonstrated beyond doubts, so other indirect models such
as competition for mitochondrial targets have to be consid-
ered [28]. The apoptosis-inhibiting effect of Bcl-2 and Bcl-
xL is opposed by BH3-only proteins.
Deregulation of Bcl-2 family members has been tightly
linked to tumorigenesis [50]. All anti-apoptotic Bcl-2 homo-
logues seem to function as oncoproteins, and pro-apoptotic
BH3-only and Bax-like proteins can act as tumor suppres-
sors (Fig. 2). This general statement is supported by a
comparative genomic hybridization (CGH) database search
for copy number gains and/or deletions of chromosomal loci
from members of the Bcl-2 family (Table 1). Chromosomal
bands harbouring Bcl-2 and Bcl-xL are clearly enhanced in
several tumor entities (indicating increased copy numbers of
the corresponding genes). In contrast, other tumors are
characterized by frequent deletions of the bak, bid and
bad loci. This indicates a specific role of these genes and
their pro- and anti-apoptotic products during the pathogen-
esis of such tumors.
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ways indirectly influence expression levels of apoptotic
regulators like the Bcl-2 family [51]. P53, for example,
normally up-regulates the pro-apoptotic Bax protein [52],
and consequently P53 inactivation leads to impaired Bax
expression. Therefore, deregulation of the Bcl-2 family
might represent a ubiquitous feature during tumorigenesis.3. Bcl-2: founding member of a new family of apoptosis-
inhibiting oncoproteins
3.1. Discovery of Bcl-2
The analysis of chromosomal rearrangements that occur
in human tumors has been among the most promising and
exciting approaches to study the molecular mechanisms that
underlie the phenomenon of malignant cell growth. This
endeavour has led to the discovery of many new genes and
has provided a considerable amount of new information
about how cells derail from normal growth control and
begin to form neoplastic tissues. The analysis of the t(14:18)
translocation breakpoint and the discovery of the bcl-2 gene,
however, had a particular impact on our understanding of
basic cell biology in normal and malignant cells [53–55].
The t(14:18) translocation is found in the majority of
follicular B-cell lymphomas and moves the bcl-2 gene from
its normal chromosomal position at 18q21 into the immu-
noglobulin heavy chain locus on chromosome 14 and
thereby into the vicinity of the immunoglobulin heavy chain
intron enhancer (Fig. 3). This results in a transcriptional
activation of the bcl-2 gene and hence the overproduction of
its protein product in B-cells. At first, bcl-2 was suspected to
be just another growth-promoting oncogene when it
emerged from the sequence of the translocation breakpoint.
However, instead of promoting cell growth, the Bcl-2
protein was found to be able to enhance cell survival and
to interfere with apoptosis [56,57] (in fact, Bcl-2 actually
inhibits the entry into the cell cycle, as discussed later).Fig. 3. Common t(14;18) bcl-2 translocation detected in human B-cell lymphom
centre B-cell lymphoma. It moves the bcl-2 gene from its normal chromosomal po
(IgH) intron enhancer EA on chromosome 14.3.2. Bcl-2 function
Bcl-2 is expressed in a wide variety of fetal tissues but in
the adult organism expression seems to be confined to cells
that are rapidly dividing and differentiating. Whereas Bcl-2
levels are high in most neurons in the developing mouse
nervous system, it decreases in many regions of the CNS
after birth but remains high in the PNS [58]. In motoneur-
ons, however, Bcl-2 has been found to be strongly expressed
during the embryonic and early postnatal period. Also well
studied are the cells of the immune system and among them
lymphocytes [59]. Bcl-2 is highly expressed in pro-B cells
(CD43+) and mature B-cells, but is down-regulated in pre-B
cells that contain cytoplasmic A chains and are preparing for
the expression of surface Ig and differentiation into mature
B-cells [60]. Bcl-2 seems to play a role in maintaining the
survival of antigen receptor selected B-cells in lymph nodes.
Thus, in addition to allowing more cells to survive and enter
the periphery, mature B-cell life spans are extended by Bcl-2
expression [61–63]. In the thymus, expression of Bcl-2 is
found throughout the medulla, but only in a few cells of the
cortex. The expression level of Bcl-2 in this tissue is again
strictly regulated and parallels the stages of T-cell differen-
tiation [64]. Bcl-2 expression is present in double negative
(DN; CD4CD8) thymocytes, decreases in double positive
(DP; CD4+CD8+) cells and again increases in single positive
(SP) T-cells. This is in accordance with the notion that DP
thymocytes are most sensitive towards apoptotic stimuli like
dexamethasone or g-irradiation and that overproduction of
Bcl-2, for example by a transgene, protects DP thymocytes
from those insults [65]. Negative selection, which is a
hallmark of the thymus and a major cause of cell death
especially for thymic DP T-cells, can be antagonized by Bcl-
2 overexpression [66–68]. In addition, the pro-apoptotic
BH3-only Bcl-2 family member Bim is essential for this
process, and the Bcl-2-like death factors Bax and Bak are
required for thymic selection [69]. In contrast to members of
the Bcl-2 family, the Death Receptor pathway seems dis-
pensable for negative selection (e.g. Ref. [70]). Bcl-2
sica Acta 1644 (2004) 229–249 233a. This chromosomal translocation is frequently found in human follicular
sition at 18q21 into close proximity to the 5V immunoglobulin heavy chain
V. Kirkin et al. / Biochimica et Biophysica Acta 1644 (2004) 229–249234expression is also important for the survival of mature T-
cells and this is demonstrated by the fact that Bcl-2-deficient
T-cells are progressively lost from the blood and peripheral
lymphoid organs [71–73].
bcl-2 knockout mice are smaller but viable, although
about half of them die by 6 weeks of age [72–74]. Later in
life they develop polycystic kidney disease, hair hypopig-
mentation and distortion of the small intestines. Kidneys
from Bcl-2-deficient mice are smaller compared to bcl-2+/
animals; they contain fewer nephrons and have smaller
nephrogenic zones [75]. The immune system in bcl-2 /
animals suffers from a loss of B- and T-cells through
apoptosis subsequent to massive involution of spleen and
thymus, resulting in a complete failure of immune function
[76]. bcl-2 / mice develop grey hair with the second hair
follicle cycle, possibly due to a defect of redox-regulated
melanin synthesis. Expression of Bcl-2 might be essential
for melanocyte maintenance after the second hair cycle [77].
A further role for Bcl-2 in controlling osteoblast phenotype
and bone deposition has been reported which might be
linked to the observed growth retardation in Bcl-2-deficient
animals [78]. In addition, results obtained with bcl-2 null
cells suggest that Bcl-2 promotes clonal expansion of
muscle cells [79].
The common explanation of how Bcl-2 (and its anti-
apoptotic homologues) inhibits apoptosis focuses on pres-
ervation of the mitochondrial membrane integrity [7].
Somehow, Bcl-2 prevents Bax/Bak oligomerization, which
would otherwise lead to the release of several apoptogenic
molecules from the mitochondrion. Like Bax and Bak, Bcl-
2 is inserted in the outer mitochondrial membrane but
whether it directly binds to these molecules under physio-
logical conditions is unclear [28]. Interaction of a BH3-only
protein with Bcl-2 allows Bax and Bak to fulfill their death-
inducing function.
There are ongoing speculations that Bcl-2 might regulate
the activation of several initiator caspases like Caspase-2
that act upstream or independently of Cyt c release from
mitochondria [28]. Currently unknown CED4-like proteins,
other than Apaf-1, might serve to oligomerize these cas-
pases. As the CED3/CED4 complex in C. elegans is
inhibited by CED9 binding, Bcl-2 might directly interact
with such adaptor proteins to prevent caspase activation.
Initially, Bcl-2 and Bcl-xL had been reported to bind to
Apaf-1 [80,81] but later publications clearly dismissed these
interactions [82,83].
Bcl-2 has not only been localized to the outer mitochon-
drial membrane but also to the nuclear envelope and the
membrane of the endoplasmic reticulum (ER). While the
functional significance of Bcl-2 localization in the nuclear
membrane is uncertain, there is accumulating evidence that
components of the ER play a role in apoptosis induction. Bcl-
2 influences calcium storage in the ER [84] and intracellular
calcium levels have been shown to affect apoptosis [85]. ER-
associated Bcl-2 is able to protect cells from various types of
apoptosis [86] and it may do so by scavenging pro-apoptoticBcl-2 family members, thereby preventing, for example,
their translocation to the mitochondria.
Very recently, siRNA studies were published showing
that silencing of bcl-2 induces massive P53-dependent
apoptosis, and that this occurs under normal cell growth
conditions without P53 induction by DNA damage [87].
Results with several cell lines indicate that bcl-2 silencing
induces P53-dependent apoptosis in colorectal carcinoma
cells in general. Bax and Caspase-2 are essential mediators
of this newly discovered Bcl-2/P53 apoptotic pathway. The
authors speculate that Bcl-2 constitutively suppresses a
novel pro-apoptotic function of P53 and that exposure to
genotoxic stress overrides Bcl-2 suppression by inducing
the transactivation potential of P53. Activated and stabilized
P53 has the capacity to alter the expression ratios of Bcl-2
[88] and Bcl-xL (down-regulated) and Bax (up-regulated
[52]) in favor of apoptosis.
3.3. Bcl-2 in the development of malignant disease
The notion that Bcl-2 may represent a prototype for a
new class of oncogenes emerged in the late 1980s with the
finding that a chromosomal translocation t(14;18) associat-
ed with human follicular B-cell lymphoma leads to tran-
scriptional activation of the bcl-2 gene [53–55]. Ensuing
analysis of experimental retrovirus-mediated Bcl-2 over-
expression in mouse bone marrow cells indicated, however,
that Bcl-2 overexpression on its own would not suffice for
tumorigenesis [57]. Rather, high levels of the Bcl-2 protein
may ensure the persistence of a cell clone with the overac-
tive bcl-2 gene until further tumorigenic mutations come
into effect. This conclusion was supported by an experiment
in which the introduction of the bcl-2 cDNA into IL-3-
dependent lymphoid and myeloid cell lines promoted cell
survival in the absence of the cytokine with the cells being
maintained in a G0 state [57].
Experiments with transgenic mice that overproduce Bcl-
2 in B-cells have strongly corroborated the hypothesis that
inhibition of programmed cell death represents one of the
critical steps in the process of tumorigenesis in a convincing
manner. Animals that bear a transcriptionally deregulated
bcl-2 transgene targeted to the lymphoid compartment show
splenic hyperplasia and a general high survival of explanted
B-cells, but at first no development of overt lymphoma
[89,90]. This resembles the human condition of follicular
lymphoma, which is an indolent disease and in later stages
progresses to a more aggressive form. If one is patient
enough, however, one can witness the rare event of the
emergence of lymphoid tumors in a bcl-2 transgenic mouse
and will find that the tumor cells show translocation of the
endogenous myc gene into the mouse immunoglobulin locus
[90]. This strongly suggests that Myc, when constitutively
expressed, can cooperate with Bcl-2 in lymphoma develop-
ment. The first test of whether such a cooperation is really
effective was performed using recombinant retroviruses to
infect bone marrow cells from El c-myc transgenic mice
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myc transgene in the lymphoid compartment and develop
lymphoma later in life, but go through a prelymphomatous
phase in their first months after birth [91]. Infection of bone
marrow from these mice at a time when they still show no
overt symptoms of lymphoma with a retrovirus carrying the
bcl-2 gene produced immortal pre-B-cell clones, whereas
control infections of bone marrow from normal mice did not
[57]. The synergism between Myc and Bcl-2 was ultimately
established by cross-breeding experiments between bcl-2
transgenic and different myc transgenic mice, where both
sets of animals had their transgene targeted to the lymphoid
lineage. The double transgenic animals became ill very soon
after birth and developed lymphoid malignancies of various
types including early B-cell precursors but also more mature
B- and T-cell lymphomas depending on the type of myc
transgene used [85,92].
A similar synergism was observed in breast tumors of
WAP-bcl-2/MMTV c-myc double transgenic mice [93].
When TRAMP (transgenic adenocarcinoma mouse prostate)
mice, which express the SV40 early genes under the control
of the probasin promoter and which develop prostate
carcinoma, are crossed with probasin-bcl-2 transgenic mice,
the resulting double transgenic animals develop carcinoma
in situ and invasive cancer with a significantly shorter
latency than TRAMP mice [94]. Interestingly, Bcl-2 can
also cooperate with the promyelocytic leukemia retinoic
acid receptor-a chimeric protein (PML-RARa) to block
neutrophil differentiation and accelerates the onset of acute
leukemia in double bcl-2/PML-RARa transgenic mice [95].
The results obtained with such mouse models resemble
the observed impact of Bcl-2 expression in human tumors.
Chromosomal bcl-2 translocations resulting in overexpres-
sion of the protein are detected in follicular centre B-cell
lymphoma and chronic lymphocytic leukaemia. Both ma-
lignancies are indolent in nature and contain predominantly
quiescent, non-cycling tumor cells [96–98]. In addition,
t(14:18) chromosomal translocations have been detected by
PCR in many normal individuals [99,100]. Like in the bcl-2
transgenic animals, these observations indicate that addi-
tional oncogenic mutations are required for the development
of B-cell lymphoma.
Overexpression of Bcl-2 is common in many types of
human cancer (including prostate, colorectal, lung, gastric,
renal, neuroblastoma, non-Hodgkin’s lymphoma, and both
acute and chronic leukaemia [101–108]) and contributes to
increased resistance to chemotherapy (see below). Never-
theless, the prognostic value of Bcl-2 overexpression seems
to depend on the tumor type and in some cases does not
correlate with progression of disease [109–111]. Lower Bcl-
2 expression has even been associated with a poorer clinical
outcome in patients with metastatic breast carcinoma [112],
and in a transgenic mouse model Bcl-2 apparently had a
tumor suppressor effect on c-Myc-induced hepatocarcino-
genesis during the emergence of neoplastic foci [113]. The
significance of such findings seems unclear but could berelated to the influence of Bcl-2 on cell cycle progression
(see below).
The ability of Bcl-2 to complement the action of well-
characterized oncoproteins like the transcription factor Myc
underlies a very important principle in tumor biology. Initial
oncogenic mutations in genes causing uncontrollable cell
proliferation inevitably activate safety mechanisms that
result in elimination of the mutated cells (e.g. Myc activa-
tion in lymphoid cells suppresses Bcl-2 expression and
results in apoptosis [114]). To this end, up-regulation of
the anti-apoptotic Bcl-2 protein ensures that overproliferat-
ing cells will survive to acquire further mutations promoting
tumorigenesis. In addition to enforced proliferation plus
impaired apoptosis, development of a full malignant phe-
notype in most cell types also requires deletion of p53
function to bypass senescence [2].4. Other anti-apoptotic Bcl-2 homologues
4.1. Bcl-xL
Bcl-xL was discovered by screening a cDNA library from
avian lymphoid cells to search for new genes with homol-
ogy to bcl-2 [115]. Bcl-xL acts as a potent inhibitor of
apoptosis and its open reading frame exhibits 44% sequence
identity to human and mouse bcl-2. Two splice variants of
the bcl-x gene exist: The long mRNA species encodes a true
Bcl-2 homologue of 233 amino acids (Bcl-xL) which
protects cells from apoptosis. The shorter mRNA encodes
a protein of 170 amino acids (Bcl-xS) which lacks the 63-aa
stretch that constitutes the BH1 and BH2 domains. Bcl-xS is
thought to act as a dominant negative regulator of either
Bcl-2 or Bcl-xL or both, and thus antagonize their protective
effects. Bcl-x is widely expressed particularly in the brain
and kidney, but expression levels are highest in the adult
thymus [13,115]. Here Bcl-x expression increases dramati-
cally when CD4-CD8- DN T-cells differentiate into DP cells
[116]. Endogenous Bcl-xL is down-regulated by both pos-
itive and negative selection signals at the DP stage of
thymocyte development, indicating that the principal pro-
tection of DP thymocytes by Bcl-xL occurs prior to selec-
tion. SP T-cells express very low to negligible amounts of
Bcl-x. This expression pattern is clearly different from Bcl-2
where expression is highest in DN T-cells and down-
regulated in DP thymocytes and high again in SP T-cells.
Bcl-xL up-regulation in activated T-cells has been linked to
the initial apoptosis resistance of these cells and subsequent
down-regulation of Bcl-xL after several days correlates with
increased sensitivity towards activation-induced cell death
(AICD) [117].
Bcl-x-deficient mice generated through gene targeting
show embryonic lethality at around day 13 of gestation with
massive apoptosis in the brain and hematopoietc tissues
[118]. Specific deletion of Bcl-xL in the lymphoid system
(Rag-2 complementation model with bcl-x / ES cells)
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Bcl-2 is deleted [116]. Only a few bcl-xL
 / T- and B-cells
form and the mice are highly susceptible to infections. It is
believed that Bcl-xL and Bcl-2 fulfill overlapping (redun-
dant), yet not identical functions and the different pheno-
types of the knockout mice support such a notion.
Like Bcl-2, Bcl-xL is localized to the outer mitochondrial
membrane and presumably inhibits apoptosis in a similar
way to Bcl-2 [119]. Increased levels of Bcl-xL are detected
in many different human cancers, including hepatocellular
[120] and renal [104] carcinoma and pancreatic cancer
[121]. Formal proof for the tumor-promoting activity of
Bcl-xL again comes from transgenic animal models. Over-
expression of Bcl-xL enhances SV40 large T antigen-medi-
ated transformation of pancreatic h cells in transgenic mice
[122]. In another mouse model, a bcl-xL transgene promotes
malignant conversion of chemically initiated skin papillo-
mas [123].
4.2. Bcl-w
Bcl-w is another member of the anti-apoptotic Bcl-2
family [124]. Like Bcl-2, it contains a C-terminal membrane
anchor and the cytosolic domain of Bcl-w consists of eight
alpha helices, which adopt a fold similar to that of Bcl-xL,
Bcl-2 and Bax proteins [125,126]. In solution, the C-
terminal helix alpha8 of Bcl-w folds into the BH3-binding
hydrophobic cleft of the protein, similar to the C-terminal
transmembrane helix of Bax. Binding and kinetic data
suggest that the C-terminal residues of Bcl-w and Bcl-xL
modulate pro-survival activity by regulating ligand access to
the groove. Interaction with pro-apoptotic BH3-only pro-
teins is likely to displace the hydrophobic C-terminal region
of both molecules.
Bcl-w is expressed in cells of myeloid, lymphoid and
epithelial origin [127]. Gene targeting experiments in mice
have demonstrated that Bcl-w is required for spermatogen-
esis and for survival of damaged epithelial cells in the gut
while it is dispensable for physiological cell death in other
tissues [128]. Bcl-w is frequently expressed in colorectal
adenocarcinomas and has been suggested to play a general
role in the progression from adenoma to adenocarcinoma in
the colorectal epithelium [129]. Bcl-w is also expressed in a
majority of infiltrative gastric adenocarcinomas and it may
suppress tumor cell death by blocking JNK activation [130].
4.3. A1/Bfl-1
The anti-apoptotic Bcl-2 homologue A1/Bfl-1 lacks a C-
terminal membrane anchor, and is preferentially expressed
in hematopoietic cells and activated endothelium in re-
sponse to inflammatory stimuli [131,132]. A1 is able to
bind the BH3-only protein Bid and this interaction seques-
ters truncated Bid to inhibit its interaction with the pro-
apoptotic Bax or Bak [133]. Up-regulation of both A1 and
the serine/threonine kinase Pim-1 is essential for in vitrotransformation and in vivo leukemogenesis mediated by
BCR/ABL [134]. The A1 gene cooperates with the E1A
oncogene in transformation of primary rodent epithelial
cells [135] and A1 has been reported to be overexpressed
in human stomach cancer tissues [131].
4.4. Mcl-1
Myeloid cell factor-1 (Mcl-1) is a death-inhibiting mem-
ber of the Bcl-2 family that is expressed in early monocyte
differentiation and can promote viability on transfection into
immature myeloid cells [136]. Mcl-1 in transgenic mice
promotes survival in a spectrum of hematopoietic cell types
and immortalization of myeloid cells [137]. Nevertheless,
Mcl-1 transgenic cells remain subject to normal in vivo
homeostatic mechanisms controlling cell survival.
Antisense experiments have demonstrated that Mcl-1
expression is required for the survival of multiple myeloma
cells [138]. A mcl-1 rather than a bcl-2 antisense therapeutic
strategy has been suggested for clinical treatment of this
plasma cell malignancy [139]. Elevated levels of Mcl-1
have also been reported for prostate cancers [106], B-cell
chronic lymphocytic leukemia (B-CLL) [140] and leukemic
relapse in AML and ALL [141]. In B-CLL patients, higher
levels of Mcl-1 were strongly correlated with failure to
achieve complete remission after single-agent therapy [140].
The cyclin-dependent kinase inhibitor flavopiridol is
currently tested in clinical trials for cancer therapy. Flavo-
piridol treatment not only leads to cell cycle inhibition, but
also induces apoptosis mediated through up-regulation of
E2F1 and repression of Mcl-1 [142] as well as increasing
levels of the pro-apoptotic Bcl-x splice variant Bcl-xS [143].5. Bax and Bak, pro-apoptotic Bcl-2 family members
targeting mitochondrial membrane integrity
In healthy primary tissue cells, Bax is a monomeric
cytosolic protein which, upon apoptotic stimulus, changes
its conformation and translocates to the mitochondria [7].
Intriguingly, in most cultured cells a significant proportion
of Bax is already located in mitochondria in the absence of
apoptotic triggers [144]. In the cytoplasm, the hydrophobic
carboxy-terminal Bax helix occludes its hydrophobic
groove formed by the BH1, -2 and -3 domains [10]. Stress
signals then provoke the C terminus to flip out and mediate
Bax integration into the mitochondria and its subsequent
oligomerization. Whether such mitochondrial Bax
oligomers form Bax pores or influence existing mitochon-
drial channels remains an open issue but, in any case,
release of apoptogenic factors like Cyt c from the mito-
chondria sets the stage for the apoptosomal amplification
loop generating Casp-9/Casp-3 activity [28].
Bak is an oligomeric integral mitochondrial membrane
protein already in living cells [145]. When cell death is
initiated, Bak also undergoes conformational changes to
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multimeric structures close to and connected with the
mitochondria but outside the mitochondrial membrane
shortly after mitochondrial Bax relocalization [146]. The
functional significance of this observation is unclear.
Bax and Bak are ubiquitously expressed in almost every
cell type. bax knockout mice develop normally and display
only slight apoptotic defects [147]. Accordingly, disruption
of bak has no obvious effect on cell death, indicating
significant functional redundancy between Bax and Bak
[16]. Indeed, bax /bak / double knockout mice display
multiple developmental defects [16] and cells lacking both
molecules cannot be induced to undergo apoptosis mediated
by BH3-only proteins [17]. Deficiency in both Bax and Bak
has also been shown to disrupt thymic selection and
lymphoid homeostasis [69]. Obviously, the presence of
either Bax or Bak is essential for apoptosis in many different
cell types.
A further role for Bax and Bak in Ca2 + homeostasis in
the ER has now been established [148]. In addition to
initiating mitochondrial dysfunction upon BH3-only protein
activation, both molecules also localize to the ER and
mediate apoptotic death in response to agents that release
Ca2 + from intracellular stores. The localization of Bcl-2 to
the ER membrane suggests that it regulates Bax and Bak ER
function.
The pro-apoptotic members of the Bcl-2 family, by virtue
of their prominent role in apoptosis induction, represent
candidate tumor suppressor genes. Thus, Bax-deficient
mice, besides cell-specific aberrations in apoptosis, also
display hyperplasia of T- and B-cell lineages, although in
the absence of spontaneous tumor formation [147]. More-
over, introduction of Bax deficiency in transgenic mice
expressing large T antigen accelerates tumorigenesis in brain
[149] and mammary tissue. The latter tumor develops
already under the conditions of haplo-insufficiency for the
bax gene [150]. Lack of functional Bax also promotes drug
resistance and oncogenic transformation in primary mouse
fibroblasts by attenuating P53-dependent apoptosis [151].
Recent evidence implicates Bax in cancer cell response
to death receptor-mediated apoptosis. Thus Bax-deficient
human colon carcinoma cells HCT116 are resistant to
TRAIL-, FasL- and TNF-a-induced cell death, which is in
stark contrast to their Bax-expressing wild-type counterparts
[152]. Moreover, treatment of the tumor cells deficient in
DNA mismatch repair with TRAIL selects for refractory
clones with bax frameshift mutations [153]. In another set of
experiments, TRAIL induced Cyt c release and apoptosis in
wild type, bid /, bax /, or bak / MEFs, but not in
bax /bak / double knockout MEFs. Interestingly, un-
like Cyt c release, TRAIL-induced Smac/Diablo release was
blocked in bid / , bax /  or bax / bak /  MEFs,
suggesting that Bax and Bak differentially regulate the
release of Cyt c and Smac/Diablo from mitochondria
[154]. The important role of Bax in tumor cell resistance
to apoptosis is supported in a further study wherein the Bax-deficient HCT116 cells were refractory to various apoptotic
stimuli, ranging from BIK and BID overexpression to UV,
staurosporine, and thapsigargin treatment [155].
Inactivation of either Bax or Bak in Ras- and E1A-
transformed mouse embryonic fibroblasts slightly increases
focus formation in the soft agar focus-formation assay.
However, when both the genes are mutated, the number of
foci is comparable to that of P53-deficient cells demonstrat-
ing the importance of the dual bax/bak inactivation for
oncogenic transformation [17]. Another group of research-
ers performed an analogous set of experiments using pri-
mary baby mouse kidney (BMK) epithelial cells. In their
hands, the expression of E1A alone was sufficient to
transform BMK cells from P53-deficient mice but is insuf-
ficient for the transformation of BMK derived from either
single (bax / or bak /) or double (bax / and bak /)
knockouts [156]. These results imply that loss of bax/bak
cannot functionally compensate for the loss of P53 in
tumors and that minimal P53 inactivation is required to
promote tumorigenesis in such bax/bak-deficient cells.
Nonetheless, the deficiency of both Bax and Bak was
sufficient to convert E1A- and dominant negative p53-
transformed BMK into highly invasive carcinoma cells
[157]. In a further study, lymphomas arising in El c-myc
transgenic mice were analysed and the results show that loss
of Bax impairs Myc-induced apoptosis and circumvents the
selection of p53 mutations during Myc-mediated lympho-
magenesis [158]. This suggests that at least in B-cells, P53
signals through Bax and that P53 inactivation is functionally
equivalent to loss of Bax in this case.
According to the results from cell culture and animal
models, down-regulation or inactivation of pro-apoptotic
Bax-like death factors is observed in several human cancers.
Decreased Bax levels in tumors are not surprising given the
fact that Bax is a transcriptional target of the tumor
suppressor P53 which is mutated in the majority of human
cancers [52]. Impaired Bax expression has been reported in
breast cancer [159], hepatocellular carcinomas [160], che-
moresistant B-CLL [161] and in a number of other tumor
types. Somatic frameshift mutations in the bax gene have
been described in colon cancers [162] and certain hemato-
poietic malignancies have been shown to possess loss-of-
function mutations of bax [163]. For several different
tumors, low Bax expression level was demonstrated as a
negative prognostic factor for patients’ survival [164–168].
Down-regulation of Bak is required for Ras-induced
transformation of intestinal epithelial cells [169]. Mutations
of the bak gene and reduced Bak levels were demonstrated
in gastric and colorectal cancers [170].
High levels of the pro-apoptotic bcl-xS splice product
have been correlated with longer overall survival in myelo-
dysplastic syndromes [171] and myeloid leukemias [172].
(Viral) Bcl-xS expression constructs were able to induce
apoptosis in cancer but not in normal cells (e.g. Refs. [173–
176]). Bcl-xS is thought to antagonize Bcl-2 and Bcl-xL by
binding and inactivating these apoptosis inhibitors, and
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Bcl-2 and/or Bcl-xL expressing cancers.6. BH3-only proteins, liberators of Bax and Bak activity
Most BH3-only proteins induce apoptosis by neutralizing
the anti-apoptotic Bcl-2-like molecules which then are not
any longer able to inhibit Bax and Bak-induced Cyt c
release [28]. One exception is Bid, which in addition to
interacting with pro-survival relatives, directly induces Bax
and Bak oligomerization at the outer mitochondrial mem-
brane [29,30]. The isolated Bim BH3 domain (but not the
entire protein) is also able to activate directly Bax and Bak
and thereby to induce Cyt c release [31]. BH3-only proteins
function upstream in the same pathway as Bax and Bak
whose presence is required for BH3-only triggered apoptotic
cell death [17].
As discussed earlier, BH3-only proteins are activated by
different mechanisms [28], among them transcriptional up-
regulation (Puma [37], Noxa [38], Hrk/DP5 [177]) and
proteolytic truncation (Bid, which upon cleavage by Cas-
pase-8 and myristoylation migrates to mitochondria [46]
where it is attracted by the cardiolipin-rich contact sites
between the outer and inner mitochondrial membranes
[178]). Bim and Bmf are normally sequestered to compo-
nents of the cytoskeleton. Release of Bim from the micro-
tubule-associated dynein motor complex upon specific
apoptotic stimuli does not require caspase activity and
may therefore constitute an initiating event in the apoptotic
signal cascade [47]. Bmf is sequestered to myosin V motors
by association with dynein light chain 2. When the cells lose
attachment, the interaction is broken and Bmf is free to find
Bcl-2 as a binding partner and to induce apoptosis (anoikis
[36]).
In healthy cells, Bad is phosphorylated by kinases like
Akt/PKB and PKA and as a consequence of this, bound and
sequestered by 14-3-3 scaffold proteins [7]. Dephosphory-
lation of Bad by Ca2 +-activated calcineurin correlates with
its dissociation from 14-3-3 in the cytosol and its subsequent
translocation to the mitochondria where Bad presumably
inactivates Bcl-xL leading to apoptosis [41].
An increasing amount of evidence also links BH3-only
proteins to oncogenesis. In mice, absence of even one bim
allele accelerates Myc-induced lymphomagenesis [28]. Bid-
deficient mice spontaneously develop a myeloproliferative
disorder which progresses from myeloid hyperplasia to a
clonal malignancy closely resembling that of chronic mye-
lomonocytic leukemia (CMML), indicating that Bid is
required for myeloid homeostasis and tumor suppression
[179]. Until now, Bid-deficient animals represent the only
knockout model for pro-apoptotic Bcl-2 family members
which spontaneously develop tumors (albeit at later age,
indicating the requirement of further mutational events).
Presumably, such tumorigenesis is not seen in single bax or
bak knockout mice because of the apparent functionalredundancy between these molecules. Given the known
downstream function of Bid in activating and oligomerizing
Bax and Bak during apoptosis, bax / bak /  double
knockout cells should be equally prone to transformation
as bid knockout cells.
Several studies show activation of BH3-only proteins in
the apoptotic response to chemotherapy, for example by
doxorubicin [180] and cisplatin [181]. Overexpression of
anti-apoptotic Bcl-2 family members inhibits such chemo-
therapy-induced cell death, as discussed later.7. Bcl-2 family members and their influence on cell cycle
entry
Results obtained with overexpressed Bcl-2 in HL60
promyelocytic leukemia cells and other mammalian cell
lines as well as with bcl-2 transgenic T- and B-lymphocytes
indicated a cell cycle inhibitory function of Bcl-2 indepen-
dent of its pro-survival function [182–185]. Cell cycle entry
(but not cell cycle progression) of mitogen-stimulated T-
and B-cells isolated from bcl-2 transgenic mice is delayed
compared to wild-type lymphocytes. In addition, overex-
pression of Bcl-2, Bcl-xL or adenovirus E1B19kD (a viral
anti-apoptotic Bcl-2 homologue) substantially delayed se-
rum-induced S phase entry of quiescent NIH 3T3 fibroblasts
[185]. The anti-apoptotic function of Bcl-2 is mechanisti-
cally distinct from its inhibitory influence on cell cycle entry
and both can be genetically separated [186,187]. A mutation
of tyrosine 28 in the Bcl-2 BH4 domain leaves the apopto-
sis-repressing function intact while abolishing its capacity to
inhibit cell cycle entry. Complementary to these results,
mature bax transgenic mouse T-cells express lower levels of
the cell cycle inhibitor P27 and enter S phase more rapidly
in response to IL-2 stimulation than control wild-type cells
[188]. It is plausible to interpret the finding that transgenic
Bax accelerates tumorigenesis in P53-deficient mice in light
of the cell cycle-promoting function of Bax [189]. Bax-
induced proliferation in this mouse model seems to operate
synergistically with the apoptosis defect contributed by the
absence of functional P53. In another animal model, Bcl-2
expression delays mammary tumor development in dime-
thylbenz(a)anthracene (DMBA)-treated (WAP-bcl-2 trans-
genic) mice [190]. The authors state that this mouse tumor
model reflects the situation seen in some human breast
cancers overexpressing Bcl-2, where expression of Bcl-2
has been shown to correlate with a lower proliferative index
in tumors. In addition, a surprising inhibition of c-Myc-
induced hepatocarcinogenesis by Bcl-2 in transgenic mice
was reported, further supporting the notion that Bcl-2 can
exert a tumor suppressor effect due to its anti-proliferative
activity [191]. As a consequence of the cell cycle entry
inhibition provoked by Bcl-2, an inverse correlation be-
tween Bcl-2 expression and cell growth fraction in human
endometrial adenocarcinoma tissue has been observed
[192].
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genic overexpression of Bcl-2 promotes myocyte prolifera-
tion [193]. It is difficult to assess how these contradictory
results correlate with the previously established anti-prolif-
erative effect of Bcl-2. This might relate to a cell- and/or
tissue-specific effect of this molecule. Induction of cell
proliferation by Bcl-2 fits with the observation that Bcl-2
overexpression down-regulates P53 function through the
formation of Mdm2/P53 inactive complexes, thereby atten-
uating P21 cell cycle inhibitor expression [193].
WAP-TAg transgenic mice present a valuable animal
model of breast cancer progression. When they are crossed
with WAP-bcl-2 transgenic mice, gain of Bcl-2 function in
TAg expressing mammary epithelia cells reduces the rate of
apoptosis throughout cancer progression, as expected [194].
Interestingly, Bcl-2 decreases mitotic activity during the
initial proliferative process but not in hyperplasias or
adenocarcinoma. Overall, retention of Bcl-2 anti-apoptotic
activity with loss of its anti-proliferative action results in
accelerated tumor formation. Of interest, the cell cycle-
inhibiting influence of Bcl-2 is lost during tumor develop-
ment, possibly by compensatory mechanisms.
Since the anti-apoptotic function of Bcl-2 is genetically
separable from its influence on cell cycle progression, it
seems feasible that certain Bcl-2 mutants with mutations
abolishing its anti-proliferative impact are selected for
during tumorigenesis. Analysis of somatic bcl-2 mutations
in human follicular lymphoma has identified amino acid
substitution in the Bcl-2 BH4 region which might eliminate
the mitosis-inhibition while leaving its anti-apoptosis func-
tion intact [195,196]. Such mutations might promote pro-
gression of Bcl-2 overexpressing tumors. It is interesting to
speculate that certain tumors acquire early mutations in-
creasing Bcl-2 activity (together with, for example, growth
promoting myc mutations), thereby preventing cell death
during the initial phase of cell transformation. During tumor
progression, additional apoptosis-inhibiting mutations might
functionally substitute for Bcl-2, which suddenly is not
required any longer to prevent tumor cell death. Hence,
cells overexpressing Bcl-2 may be selected against because
of its inhibitory influence on cell cycle progression. Biop-
sies obtained at the time when the established tumor is
detected would appear inconspicuous for Bcl-2 expression
despite the initial and transient tumor-promoting Bcl-2 up-
regulation, misleading to the interpretation that increased
Bcl-2 levels were not important for development of the
particular tumor.
How exactly Bcl-2 family members mechanistically
interfere with cell cycle regulation is presently unclear.
Bax and Bcl-2 modulate Cdk2 activation during thymocyte
apoptosis [197]. Cdk2 kinase activity efficiently blocks cell
death via certain apoptosis pathways, while overexpression
of Cdk2 accelerates cell death. Whether the influence of Bax
and Bcl-2 on Cdk2 activation somehow also accounts for
their impact on cell proliferation is an unresolved issue.
Elevation of the cell cycle inhibitor p27 and inhibition of G1cyclin-dependent kinases upon Bcl-2 and Bcl-xL expression
have also been reported [198].
Another clue comes from experiments with the anti-
apoptotic Bcl-2 homologue Mcl-1. Overexpression of
Mcl-1—like Bcl-2 and Bcl-xL—significantly inhibits cell
cycle progression through S-phase [199]. Remarkably, Mcl-
1 is the only Bcl-2 family member shown to bind to the cell
cycle regulator proliferating cell nuclear antigen (PCNA)
and this interaction seems to mediate its impact on cell cycle
progression.8. The Bcl-2 family and its influence on radiation and
chemotherapy resistance
One of the major limitations of clinical cancer treatment
is the marked ability of human tumors to develop and
sustain resistance to cytotoxic drugs and DNA damaging
radiation. The fact that defects in apoptosis can promote
drug resistance downstream of the drug–target interaction
strongly suggests a causal relationship between apoptosis
and drug-induced cytotoxicity [200]. In this context, up-
regulation of the anti-apoptotic and down-regulation of the
pro-apoptotic Bcl-2 family members in tumors have been
associated with their decreased susceptibility to the action of
chemotherapeutics [180,201–208] and to increased radio-
resistance [209–212] (Fig. 4). Significantly, abrogation of
Bcl-2/Bcl-xL expression as well as reinforcement of Bax
expression not only cause tumor regression but also render
them more sensitive to apoptosis-inducing treatment (see
also next section on clinical therapies). Mouse embryonic
fibroblasts lacking both Bax and Bak are completely resis-
tant to etoposide- and staurosporine-induced apoptosis, as
they are to any BH3-only protein triggered apoptotic stim-
ulus [17,207]. Loss of Bax alone in colon carcinoma cells
results in an increase in resistance to the chemotherapeutic
agent 5-fluorouracil [208].
Loss of various tumor suppressor genes such as p53,
WT1 and PTEN has been shown to cause Bcl-2 over-
expression [213]. Since p53 can directly induce transcrip-
tional activation of pro-apoptotic molecules including Bax
[52], Puma [37] and Noxa [38], the expression level of Bcl-
2 family members may indirectly be affected in tumors by
mutated signal transduction pathways. Accordingly, func-
tional P53 deficiency interferes with the cell’s ability to
undergo apoptosis in response to chemotherapeutics and
radiation.
Recently it has been shown that a senescence programme
controlled by P53 and P16INK4a contributes to the outcome
of cancer therapy [214]. The authors demonstrate that both
apoptosis and senescence add to the tumor cells’ response to
cyclophosphamide treatment. This explains why in their
hands tumor cells overexpressing Bcl-2 fail to regress
following therapy (see Fig. 4) but because of senescence
induction do not progress for extended periods. One con-
clusion drawn from this study is that senescence can serve
Fig. 4. In vivo imaging of Bcl-2-mediated drug resistance in murine lymphomas. Murine GFP-tagged El-myc lymphoma cells were infected either with control
or with a bcl-2 retrovirus and transplanted into syngeneic recipient mice. Lymphoma-bearing animals were treated at comparable tumor burdens (day 0) with a
single dose of cyclophosphamide (CTX) and monitored by whole-body fluorescence imaging. Control tumors responded rapidly to CTX, with no GFP
fluorescence detectable by 24 h or thereafter. bcl-2-transduced tumors displayed virtually no response to CTX due to apoptosis prevention by Bcl-2 (reprinted
in modified form from Ref. [214], with kind permission from the authors and Elsevier).
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Bcl-2 to enhance clonogenic survival following drug treat-
ment in vitro.9. Clinical anticancer therapies involving Bcl-2 family
members
As we already discussed in the previous sections, deregu-
lated Bcl-2 family proteins contribute to the oncogenic
transformation of normal cells. Several key Bcl-2 family
members, such as Bcl-2, Bcl-xL and Bax, have recurrently
been found misexpressed in tumor tissue. Moreover, it is the
capability of neoplastic cells to remain refractory to various
apoptotic cues that creates important prerequisites for them
to develop those ultimate manifestations of cancer that we
know as metastasis. Current anticancer protocols used in
clinic, such as radio- and chemotherapy, aim to eliminate
swiftly proliferating tumor cells by ‘‘encouraging’’ fulfill-
ment of their intrinsic apoptotic programmes. In this con-
text, overexpression of Bcl-2 and Bcl-xL inasmuch as loss of
Bax and/or Bak has been linked to the acquired resistance oftumors to radiation and chemotherapy. Therefore, it has
been proposed that functional blockade of either the anti-
apoptotic Bcl-2 family members or overexpression of the
pro-apoptotic ones could possibly restore the apoptotic
machinery in tumor cells and/or sensitize these tumors to
chemo- and radiotherapies.
The development of novel antitumor therapies targeting
Bcl-2 family members is an objective pursued by many
research groups. Their work follows three major strategies:
(1) down-regulation of the anti-apoptotic Bcl-2 family
proteins by targeting their mRNAs; (2) interference with
the function of anti-apoptotic Bcl-2 family members at the
protein level through the use of Bcl-2-binding compounds;
(3) induction of apoptosis by introduction of pro-apoptotic
Bcl-2 family molecules.
The first approach specifically targeting Bcl-2 family
members is based on the fact that antisense oligonucleotides
are able to hybridize to target mRNAs, leading to their
degradation and hence decreasing de novo synthesis of Bcl-
2 protein. One such antisense oligonucleotide, G3139 (an
18-mer phosphorothioate oligonucleotide, Oblimersen, Gen-
asense, Genta Inc.), was shown to reduce Bcl-2 protein
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vitro. The concomitant 80–95% increase in cell death was
attributed to an enhanced apoptosis rate, with cells exhibit-
ing mitochondrial membrane depolarisation and caspase
activation. These breast tumor cells treated with G3139
were also more sensitive to the action of cytotoxic drugs
[215]. Furthermore, in SCID mouse xenograft models,
G3139 was able to reduce growth of several transplanted
human tumors corroborating the in vitro data [216,217].
G3139 was first introduced in clinical trials to treat non-
Hodgkin lymphoma. The result achieved was modest in that
of the 21 patients who received the treatment, only one
patient showed a complete response and two displayed a
partial response. The reduction in Bcl-2 protein levels was
observed in only about half of the patients [218]. However,
the therapy has had only limited toxicity impact and was
extended to other tumors, such as melanoma, multiple
myeloma, CLL, and lung cancer. Clinical trials with these
tumor types are now underway to determine the efficacy and
safety of this anticancer agent either alone or in combination
with cytotoxic drugs in patients (e.g. reviewed in Ref.
[219]).
Logically, Bcl-xL has also become a target for the
antisense oligonucleotide-based anticancer approach and
several recent studies were able to demonstrate the potential
of this strategy for induction of tumor cell apoptosis in vitro.
Thus, growth of various melanoma cell lines, which express
high levels of Bcl-xL, could be inhibited upon treatment
with a bcl-xL-directed antisense oligonucleotide [220]. One
problem in such a strategy was immediately evident as
normal melanocytes were shown to express high levels of
both Bcl-2 and Bcl-xL. Their viability was consequently
also reduced, which likely presents a side effect of such a
therapy. In addition to having a direct effect on apoptosis,
bcl-xL antisense oligonucleotides also enhance chemosensi-
tivity of melanoma cells [221]. Interestingly, one bcl-xL
antisense oligonucleotide was able to shift the splicing
pattern of bcl-x pre-mRNA from bcl-xL to bcl-xS, which in
turn is likely to further promote apoptotic cell death in the
cells studied [222].
Based on high homology of some mRNA regions of bcl-
2 and bcl-xL, it was attempted to design antisense oligonu-
cleotides with dual specificity that would target the two
major anti-apoptotic proteins involved in tumorigenesis at
the same time. Pre-clinical testing of such dual-specificity
antisense oligonucleotides showed simultaneous down-reg-
ulation of Bcl-2 and Bcl-xL as well as apoptosis induction in
various tumors both in vitro and in vivo [223–225].
Since the selection process operating in a tumor cell
population will most likely lead to the appearence of cell
clones resistant to the anti-Bcl-2/Bcl-xL therapy, it may be
necessary to apply a combinatorial antisense strategy in
which both proliferation and apoptosis pathways would be
targeted. Such approaches have already been undertaken in
vitro [226] and in nude mice xenograft models in vivo
[227], demonstrating in the latter case not only dramatictumor regression but also enhanced sensitivity to cytotoxic
drugs. For future application, antisense strategies may be
replaced by RNAi approaches using siRNA oligonucleoti-
des. For both methods efficient in vivo delivery and stability
remains a problem but siRNA proves to be highly specific
and efficient already when used with low concentrations.
The antisense oligonucleotides have not been the only
means by which the activity of Bcl-2/Bcl-xL proteins is
targeted in tumor cells. Very recently, another strategy to
inhibit Bcl-2 translation that involves use of synthetic
ribozymes has been developed. Ribozymes are catalytic
RNA molecules that inhibit gene expression by cleaving
specific RNA sequences. Luzi et al. [228] used such a
synthetic rybozyme in a Bcl-2-overexpressing human lym-
phoma cell line with a view of targeting the A +U-rich
regulative element of bcl-2 mRNA, which is involved in the
bcl-2 gene switch-off during the process of apoptosis. These
apoptosis-resistant lymphoma cells demonstrated strong
reduction in Bcl-2 mRNA and protein levels and increased
death by apoptosis.
To interfere with Bcl-2 function at the protein level,
Wang et al. developed alternative approaches in which small
molecules bind to and inactivate the overexpressed Bcl-2
protein. In one set of experiments, a cell permeable Bcl-2
binding peptide was designed by chemically attaching a
fatty acid to a peptide derived from the pro-apoptotic BH3-
only protein Bad, which inhibited growth of bcl-2 trans-
fected human myeloid leukemia HL-60 cells both in vitro
and in vivo [229]. In another study, a small chemical
compound, HA14-1, was synthesized by using a computer
screening strategy based on the predicted structure of the
Bcl-2 protein. HA14-1 acts as a non-peptidic ligand of Bcl-2
and the compound proved to efficiently induce apoptosis in
Bcl-2-overexpressing HL-60 cells in vitro [230]. One mech-
anism by which Bcl-2 is believed to suppress apoptosis is
through its ability to heterodimerize with pro-apoptotic Bcl-
2 family members (e.g. Bax), thereby antagonizing their
function. It seems likely that Bcl-2-interacting molecules
interfere with such Bcl-2/Bax heterodimerization and induce
cell death, e.g. by binding to the hydrophobic Bcl-2 pocket
(formed by the BH1, BH2 and BH3 domains) which is
occupied by Bak and Bax BH3 peptides. This hypothesis is
supported by the work of Finnegan et al. [231] which shows
that synthetic peptides derived from the BH3 domain of pro-
apoptotic Bcl-2 family members (and which mimick Bax/
Bak binding to Bcl-2) prevent Bak/Bcl-2 heterodimerization
and induce apoptosis in prostate carcinoma cells 48 h after
introduction of the synthetic peptides.
In other studies, small-molecule inhibitors (among them
antimycin A) have been identified that bind to Bcl-2 and
Bcl-xL and that disrupt the interaction between Bcl-2/Bcl-xL
and the BH3 domain of pro-apoptotic Bcl-2 family mem-
bers, thereby inducing cell death [232–234]. These com-
pounds might serve as lead molecules to find ‘‘drugable’’
small molecules with even higher affinities for Bcl-2 and
Bcl-xL. Small molecular weight (MW) drugs are generally
V. Kirkin et al. / Biochimica et Biophysica Acta 1644 (2004) 229–249242preferred clinical tools because of cheap production and
easy delivery (typical problems usually associated with
ribozymes and peptides).
Since the cell’s decision to undergo apoptosis—among
other things—depends on the ratio between pro- and anti-
apoptotic Bcl-2 family members, not only by down-regula-
tion of Bcl-2/Bcl-xL but also by up-regulation of pro-
apoptotic Bax, Bak and Bcl-xS, it has been attempted to tilt
this ratio in tumor cells towards apoptosis induction. Clarke
et al. [173] demonstrated that introduction of Bcl-xS using
an adenovirus vector efficiently and specifically killed
multiple carcinoma cell lines, while leaving normal hema-
topoietic cells unaffected. On the basis of these observa-
tions, it was concluded that such a strategy could be used for
purging bone marrow from cancer patients undergoing
autologous bone marrow transplantation. Adenovirus-based
delivery of pro-apoptotic Bcl-2 proteins has also been
applied for introduction of Bax and Bak proteins into
several cancer cell lines. Thus, selective expression of Bax
in LNCaP prostate cancer cells resulted in 85% reduction in
cell viability through induction of apoptosis. Importantly,
overexpression of the Bcl-2 protein in this cell line could not
prevent cell death, indicating the potency of such a strategy
[235]. Similarly, introduction of the bak gene into mesothe-
lioma cells led to significant decrease in cell viability that
was associated with induction of apoptosis [236]. Rein-
forcement of pro-apoptotic Bcl-2 family member activity in
tumor cells also bears a promise for their sensitization
towards radio- and chemotherapies. Keeping in line with
this idea, Sugimoto et al. [237] provided evidence that a
cisplatin-resistant head and neck squamous cell carcinoma
(SCC) cell line transfected with bax regained the same
cisplatin sensitivity as the parental cell line in vitro. The
in vivo percutaneous transfer of the bax gene by a ‘‘gene
gun’’ technique into cisplatin-resistant head and neck mouse
SCC tumors inhibited their growth and potently sensitized
them to cisplatin treatment.
The potential use of BH3 domain peptide activators of
apoptosis (or BH3 mimetics) warrants a special mentioning
in the context of clinical anticancer therapies. Synthetic
peptides derived from BH3 domains of pro-apoptotic Bcl-
2 family members promote apoptosis in (cancer) cells
[231,238–243]. While Bid-like BH3 domains activate Bax
and Bak directly (and induce apoptosis), Bad-like domains
sensitize mitochondria for apoptosis by occupying the
pocket of anti-apoptotic Bcl-2/Bcl-xL [31]. The latter reset
the susceptibility of tumor cells protected by anti-apoptotic
Bcl-2 family members, but would require a second apoptotic
signal to initiate an activating BH3-only protein and to
induce cell death. The need for a second signal provides
the opportunity to utilize tumor cell-selective pathways for
specific killing of transformed cells. Selectivity is of great
concern when using pro-apoptotic drugs in tumor therapy,
and unspecific killing of normal cells is drastically demon-
strated in the case of systemic in vivo delivery of anti-
CD95/Fas antibodies to mice which results in rapid andlethal liver failure [244]. Since the therapeutic application of
peptides bears several problems (insufficient stability and
delivery, expensive synthesis), small drugs mimicking spe-
cific BH3 domains would represent attractive candidate
tools for clinical trials.
In conclusion, it is well conceivable that novel anticancer
strategies manipulating Bcl-2 family function will eventu-
ally make it possible to subvert a tumor’s ability to persist
and ‘‘thrive’’ in the face of major apoptotic insults, such as
the transformation per se, radiation and cytotoxic drugs.
During preparation of this manuscript a further study on
bad knockout mice was published emphasizing the potential
of BH3-only proteins to act as tumor suppressors (A.M.
Ranger, J. Zha, H. Harada, S.R. Datta, N.N. Danial, A.P.
Gilmore, J.L. Kutok, M.M. Le Beau, M.E. Greenberg, S.J.
Korsmeyer, Bad-deficient mice develop diffuse large B cell
lymphoma, PNAS 100 (2003) 9324).Acknowledgements
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